SCHEMBL2174676

SCHEMBL2174676

CCOC(=O)c1csc(C(C)NC(=O)COc2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
RAB9A P51151 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
HSP90AA1 P07900 2/20 0.48
MAPK1 P28482 2/20 0.48
ABCB1 P08183 2/20 0.46
NPC1 O15118 3/20 0.46
ALDH1A1 P00352 3/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
PLA2G4A P47712 1/20 0.44
LMNA P02545 2/20 0.43
ANO1 Q5XXA6 1/20 0.43
MCHR1 Q99705 2/20 0.42
PTPRB P23467 1/20 0.42
TP53 P04637 1/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2174510 0.89 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1CYP1A2CYP2C19MCHR1
SCHEMBL2174194 0.85 PTPRB (0.51) MAPTRAB9ASMN1; SMN2HSP90AA1MAPK1
SCHEMBL5669774 0.80 RAB9A (0.47) MAPTRAB9ASMN1; SMN2HSP90AA1MAPK1
SCHEMBL5668327 0.79 RAB9A (0.53) MAPTRAB9ASMN1; SMN2HSP90AA1MAPK1
SCHEMBL4835852 0.78 ABCB1 (0.56) MAPTRAB9ASMN1; SMN2HSP90AA1MAPK1
SCHEMBL18003076 0.76 MAPT (0.76) MAPTRAB9ASMN1; SMN2HSP90AA1MAPK1
SCHEMBL2171648 0.76 TRPV1 (0.56) RAB9ASMN1; SMN2NPC1ALDH1A1TP53
SCHEMBL18002737 0.76 MAPT (0.56) MAPTRAB9ASMN1; SMN2HSP90AA1MAPK1
SCHEMBL1058980 0.74 ABCB1 (0.73) MAPTRAB9ASMN1; SMN2HSP90AA1MAPK1
SCHEMBL13535505 0.74 ABCB1 (0.73) MAPTRAB9ASMN1; SMN2HSP90AA1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed
EP-1730128-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-12-13 EP disclosed
WO-2005097765-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 MAPT 4524/4885RAB9A 2862/4885SMN1; SMN2 4564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.